streep tussen2


‘It’s time to change the treatment paradigm:

HCV testing and treatment in community

and low threshold settings’

HVC seminar 3-4 November 2016, Paris, France

3 November 2016
Headquarters oh Medecins du Monde, 62 rue Marcadet, Paris, France
(18éme district, subway ligne 4 Marcadet Poissonniers station)

4 November 2016
GAIA DCR, 2 bis rue Ambroise PARE, Paris, France
(near Gare du Nord, 10ème district)

In cooperation with the Auto-Support des Usagers de Drogues (ASUD), Association Gaia and the European Network of People Who Use Drugs (EURONPUD), the Correlation Hepatitis C Initiative organises a seminar for community members, harm reduction workers, HCV researchers and activists engaged in HCV prevention, treatment and advocacy. The seminar’s aim is to provide insights in newest developments in HCV testing and treatment opportunities, to present good practices of community and harm reduction based HCV activities and to exchange and discuss future opportunities.

The second day will take place in a venue of the first drug consumption room (DCR) in France (to be opened in October), and will highlight the concept and approach of DCR’s and presenting results of a survey on hcv awareness in drug consumption rooms worldwide, carried out by SidneyMSIC and the Drug Consumption Room Network.

En collaboration avec l'Auto-Support des Usagers de Drogues (ASUD), l'Association Gaia et l'European Network of People Who Use Drugs (EURONPUD), la Correlation Hepatitis C Initiative organise un séminaire pour les membres de la communauté des travailleurs en réduction des risques, des chercheurs HCV et des militants investis dans la défense, la prévention et le traitement de l'HCV. L'objectif de ce séminaire est de partager les dernières avancées en terme de dépistage et d'opportunités de traitement, de présenter des bonnes pratiques, de discuter et d'échanger sur des perspectives futures.

La seconde journée se tiendra dans la première salle de consommation à moindre risque (SCMR) qui ouvrira en France en octobre prochain. Cette journée sera l'occasion de présenter le concept et l'approche de la SCMR.

Pour le détail du programme et inscription, visitez notre site

L'évènement sera traduit en français de manière simultanée.


There is the opportunity to include a small number of additional presentations to the programme. If you want to do so, please submit your abstract to This email address is being protected from spambots. You need JavaScript enabled to view it. before the 20th of September. Attendance costs of speakers can be covered on request.

Registration is free of charge.

More questions?
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.


streep tussen2


The time to foster a unified global response

to the hepatitis C epidemic is now!

  • Develop Targeted HCV Strategies and Action Plans
  • Provide Access to HCV Testing, Treatment and Care Services
  • Scale-up Harm Reduction, evidence and rights and Community-Based Programs
  • Decriminalize People Who Use Drugs
  • Meaningful inclusion of People who Inject Drugs and their organisations
  • Increase Health and HCV Literacy



streep tussen2


Hepatitis C among drug users in Europe:

epidemiology, treatment and prevention

EMCDDA, Lisbon, July 2016

HepC insights cover pageEMCDDA published a new INSIGHT report: epidemiology, treatment and prevention provides a timely contribution to raising awareness of the hepatitis C epidemic in Europe and the opportunities now opening up to tackle this problem decisively. A state of the art review of the epidemiology of hepatitis C virus (HCV) infection in Europe and an overview of the way preventive measures are currently implemented in European countries set the scene. International experts address the treatment of HCV infection among people who inject drugs, with an emphasis on how we encourage uptake and deliver effective outcomes. Implementation issues are also explored, as are the complementary roles of treatment and prevention. The new medicines and treatment regimens driving the transformation in the HCV treatment landscape are reviewed in detail. The challenges of scaling up HCV treatment and successfully involving drug using patients is explored from different viewpoints, including that of the drug user.

Read more: